medinfoАктуальные проблемы теоретической и клинической медициныActual Problems of Theoretical and Clinical Medicine2790-12892790-1297Казахстанско-Российский медицинский университет10.24412/2790-1289-2023-4-28-34medinfo-376Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCLINICAL CASEСиндром Гийена Барре: клинический случайGuillain-Barré Syndrome: Clinical Casehttps://orcid.org/0009-0002-5179-9353ШамсиддиноваК. З.ShamsiddinovaK. Z.

Шамсиддинова Камила Зарбитдиновна – резидент второго курса

Алматы

Shamsiddinova Kamila Zarbitdinovna – second-year resident

Almaty

shamsiddinova.kamila@mail.ruhttps://orcid.org/0009-0001-8267-6850МажитД. Н.MazhitD. N.

Мажит Нурсултан Дуйсебайулы – резидент второго курса

Алматы

Mazhit Nursultan Duisebaiuly – second-year resident

Almaty

mazhitn1996@gmail.comhttps://orcid.org/0000-0002-4912-4229ЛепесоваМ. М.LepesovaM. M.

Лепесова Маржан Махмутовна – доктор медицинских наук, профессор, заведующая кафедрой неврологии

Алматы

Lepesova Marzhan Makhmutovna – Doctor of Medical Sciences, Professor, Head of the Neurology Department

Almaty

mar.izzhan@mail.ruhttps://orcid.org/0000-0001-5490-6869КажаубаеваМ. А.KazhaubaevaM. A.

Қажаубаева Манчук Амантаевна – ассистент кафедры неврологии

Алматы

Kazhaubaeva Manchuk Amantaevna – Assistant Professor of Neurology

Almaty

manshuk_md90@mail.ruНУО «Казахстанско-Российский медицинский университет»КазахстанNEI «Kazakh-Russian Medical University»Kazakhstan202329122023042835Copyright © Шамсиддинова К.З., Мажит Д.Н., Лепесова М.М., Кажаубаева М.А., 20232023Шамсиддинова К.З., Мажит Д.Н., Лепесова М.М., Кажаубаева М.А.Shamsiddinova K.Z., Mazhit D.N., Lepesova M.M., Kazhaubaeva M.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://kazrosmedjournal.krmu.edu.kz/jour/article/view/376

Синдром Гийена-Барре (СГБ) представляет собой паралитическую периферическую нейропатию с годовой заболеваемостью от 0,81 до 1,89 случаев (медиана – 1,11) на 100 000 человекв мире. Внутрибольничная смертность от СГБ составляет около 2,6-2,8 %. Среди факторов риска выделяют степень выраженности слабости при поступлении, время достижения максимальнойинвалидности, необходимость искусственной вентиляции легких (ИВЛ), пожилой возраст, а также наличие легочных и сердечных осложнений.Приводятся положительные результаты лечения одной из самых частых острых полинейропатий – острой воспалительной полирадикулонейропатии аутоиммунного генеза, или синдрому ГийенаБарре. Подробно изложена патоморфология, дана характеристика различных клинических вариантов, представлены диагностические критерии и методы лечения синдрома Гийена- Барре.Описан случай острой воспалительной демиелинизирующие полирадикулонейропатии с развитием нижнего парапареза. Клиническое улучшение отмечалось с третьих суток, а полное восстановление неврологического дефицита, как клинически, так и по данным ЭНМГ, через 3 месяца.

Guillain-Barré syndrome (GBS) is a paralytic peripheral neuropathy with an annual incidence of 0.81 to 1.89 cases (median: 1.11) per 100,000 people worldwide. The in-hospital mortality rate from GBS is approximately 2.6-2.8%. Risk factors include the severity of weakness at admission, time to reach maximum disability, the need for mechanical ventilation (MV), advanced age, as well as the presence of pulmonary and cardiac complications. Positive treatment outcomes are presented for one of the most common acute polyneuropathies—acute inflammatory polyradiculoneuropathy of autoimmune origin, orGuillain-Barré syndrome. The pathomorphology is described in detail, the characteristics of various clinical variants are provided, and the diagnostic criteria and treatment methods for Guillain-Barré syndrome are presented. A case of acute inflammatory demyelinating polyradiculoneuropathy with the development of lower paraparesis is described. Clinical improvement was noted from the third day, and complete recovery of neurological deficits, both clinically and according to ENMG data, was observed after 3 months.

клинический случайсиндром Гийена Барреклиникадиагностикалечениеclinical caseGiеn Barre syndromeclinicdiagnosistreatmentReferencesBenedetti L., Briani C., Beronio A., Massa F., Giorli E., Sani C. et al. Increased incidence of axonal Guillain-Barre syndrome in la spezia area of Italy: a 13-year follow-up study // Journal of the Peripheral Nervous System. – 2019. – Vol. 24. – P. 80-86. – DOI: 10.1111/jns.12292.Benedetti, L., Briani, C., Beronio, A., Massa, F., Giorli, E., Sani, C. et al. (2019). Increased incidence of axonal Guillain-Barre syndrome in la spezia area of Italy: a 13-year follow-up study. Journal of the Peripheral Nervous System, 24, 80-86, DOI: 10.1111/jns.12292.Van Den Berg B., Bunschoten C., Van Doorn P. A., Jacobs B. C. Mortalityin Guillain-Barresyndrome // Neurology. – 2013. – Vol. 80. – P. 1650-1654. – DOI: 10.1212/wnl.0b013e3182904fccVan Den Berg, B., Bunschoten, C., Van Doorn, P. A. and Jacobs, B. C. (2013). Mortalityin Guillain-Barre syndrome // Neurology, 80, 1650-1654, DOI: 10.1212/wnl.0b013e3182904fcc.Alshekhlee A., Miles J. D., Katirji B., Preston D. C., Kaminski H. J. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals // Neurology. – 2009. – Vol. 72. – P. 15481554. – DOI: 10.1212/wnl.0b013e3181a41211.Alshekhlee, A., Miles, J. D., Katirji, B., Preston, D. C. and Kaminski, H. J. (2009). Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology, 72, 1548-1554, DOI: 10.1212/wnl.0b013e3181a41211.Sejvar J. J., Baughman A. L., Wise M., Morgan O. W. Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis // Neuroepidemiology. – 2011. – Vol. 36. – P. 123-133. – DOI: 10.1159/000324710.Sejvar, J. J., Baughman, A. L., Wise, M. and Morgan, O. W. (2011). Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology, 36, 123-133, DOI: 10.1159/000324710.Wakerley B. R., Yuki N. Infectious and noninfectious triggers in Guillain-Barre syndrome // Expert Review of Clinical Immunology. – 2013. – Vol. 9. – P. 627-639. – DOI: 10.1586/1744666x.2013.811119.Wakerley, B. R. and Yuki, N. (2013). Infectious and noninfectious triggers in Guillain-Barre syndrome. Expert Review of Clinical Immunology, 9, 627-639, DOI: 10.1586/1744666x.2013.811119.Khan F., Pallant J. F., Ng L., Bhasker A. Factors associated with long-term functional outcomes and psychological sequelae in Guillain-Barre syndrome // Journal of Neurology. – 2010. – Vol. 257. – P. 2024-2031. – DOI: 10.1007/s00415-010-5653-x.Khan, F., Pallant, J. F., Ng, L. and Bhasker, A. (2010). Factors associated with long-term functional outcomes and psychological sequelae in Guillain-Barre syndrome. Journal of Neurology, 257, 20242031, DOI: 10.1007/s00415-010-5653-x.Khan F., Amatya B. Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review // European Journal of Physical and Rehabilitation Medicine. – 2012. – Vol. 48. – P. 507-522.Khan, F. and Amatya, B. (2012). Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review. European Journal of Physical and Rehabilitation Medicine, 48, 507-522.Van Den Berg B., Storm E. F., Garssen MJP., Blomkwist-Markens P. H., Jacobs B. C. Clinical outcome of Guillain-Barre syndrome after prolonged mechanical ventilation // Journal of Neurology, Neurosurgery and Psychiatry. – 2018. – Vol. 89. – P. 949-954. – DOI: 10.1136/jnnp-2018-317968.Van Den Berg, B., Storm, E. F., Garssen, MJP., Blomkwist-Markens, P. H. and Jacobs, B. C. (2018). Clinical outcome of Guillain-Barre syndrome after prolonged mechanical ventilation. Journal of Neurology, Neurosurgery and Psychiatry, 89, 949-954, DOI: 10.1136/jnnp-2018-317968.Oladiran O., Shi X. Q., Yang M., Fournier S., Zhang J. Inhibition of TLR4 signaling protects mice from sensory and motor dysfunction in an animal model of autoimmune peripheral neuropathy // Journal of Neuroinflammation. – 2021. – Vol. 18(1). – P. 77. – DOI: 10.1186/s12974-021-02126-x.Oladiran, O., Shi, X. Q., Yang, M., Fournier, S. and Zhang, J. (2021). Inhibition of TLR4 signaling protects mice from sensory and motor dysfunction in an animal model of autoimmune peripheral neuropathy. Journal of Neuroinflammation, 1-17.Leonhard S. E. et al. Diagnosis and management of Guillain-Barré syndrome in ten steps // Nature Reviews Neurology. – 2019. – Vol. 15(11). – P. 671683. – DOI: 10.1038/s41582-019-0250-9.Leonhard, S. E. et al. (2019). Diagnosis and management of Guillain-Barré syndrome in ten steps. Nature Reviews Neurology, 15 (11), 671-683, DOI: 10.1038/s41582-019-0250-9.Berciano J. Axonal degeneration in Guillain-Barré syndrome: a reappraisal // Journal of Neurology. – Vol. 268(10). – P. 3728-3743. – DOI: 10.1007/ s00415-020-10034-y.Berciano, J. (2020). Axonal degeneration in Guillain–Barré syndrome: a reappraisal. Journal of Neurology, 268(10), 3728-3743, DOI: 10.1007/s00415-020-10034-y.Martín-Aguilar L., Pascual-Goñi E., Querol L. Autoantibodies in immune-mediated inflammatory neuropathies // Medicina Clínica (English Ed.). – 2019. – Vol. 153(9). – P. 360-367. – DOI: 10.1016/j.medcle.2019.06.015.Martín-Aguilar, L., Pascual-Goñi, E. and Querol, L. (2019). Autoantibodies in immune-mediated inflammatory neuropathies. Medicina Clínica (English Ed.), 153(9), 360-367, DOI: 10.1016/j.medcle.2019.06.015.Синдром Гийена Барре [Электронный ресурс] // Teledoctor 24. [Website]. – 2022. – URL: https://teledoctor24.ru/libpage/26-sindromgiyena-barre/ (дата обращения: 11.10.2023).Sindrom Gijena Barre (2022). Teledoctor 24. [Website]. Retrieved October 11, 2023, from https://teledoctor24.ru/libpage/26-sindrom-giyena-barre/ (In Russian).Cao-Lormeau V. M. et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: A case-control study // Lancet. – 2016. – Vol. 387(10027). – P. 1531-1539. – DOI: 10.1016/S0140-6736(16)00562-6.Cao-Lormeau, V. M. et al. (2016). Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: A case-control study. Lancet, 387(10027), 1531-1539, DOI: 10.1016/S01406736(16)00562-6.Van Den Berg B. et al. Guillain-Barré syndrome associated with preceding hepatitis E virus infection // Neurology. – 2014. – Vol. 82(6). – P. 491-497. – DOI: 10.1212/WNL.0000000000000111.Van Den Berg, B. et al. (2014). Guillain-Barré syndrome associated with preceding hepatitis E virus infection. Neurology, 82(6), 491-497, DOI: 10.1212/WNL.0000000000000111.Keddie S. et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome // Brain. – 2021. – Vol. 144(2). – P. 682-693. – DOI: 10.1093/brain/awaa433.Keddie, S. et al. (2021). Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain, 144(2), 682693, DOI: 10.1093/brain/awaa433.Restrepo-Jiménez P., Rodríguez Y., González P., Chang C., Gershwin M. E., Anaya J. M. The immunotherapy of Guillain-Barré syndrome // Expert Opinion on Biological Therapy. – 2018. – Vol. 18(6). – P. 619-631. – DOI: 10.1080/14712598.2018.1468885.Restrepo-Jiménez, P., Rodríguez, Y., González, P., Chang, C., Gershwin, M. E. and Anaya, J. M. (2018). The immunotherapy of Guillain-Barré syndrome. Expert Opinion on Biological Therapy, 18(6), 619-631, DOI: 10.1080/14712598.2018.1468885.Koike H. et al. Ultrastructural mechanisms of macrophage-induced demyelination in Guillain-Barré syndrome // Journal of Neurology, Neurosurgery and Psychiatry. – 2020. – Vol. 91(6). – P. 650659. – DOI: 10.1136/jnnp-2019–322479.Koike, H. et al. (2020). Ultrastructural mechanisms of macrophage-induced demyelination in Guillain-Barré syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 91(6), 650-659, DOI: 10.1136/jnnp-2019–322479.Griffin J. W., et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome // Journal of Neurocytology. – 1996. – Vol. 25(1). – P. 33-51. – DOI: 10.1007/BF02284784.Griffin, J. W. et al. (1996). Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. Journal of Neurocytology, 25(1), 33-51, DOI: 10.1007/BF02284784.Пирадов М. А., Авдюнина И. А. Синдром Гийена - Барре: проблемы лечения и терминологии // Неврологический журнал. – 1996. – № 3. – С. 33-36Piradov, M. A., Avdjunina, I. A. (1996). Sindrom Gijena-Barre: problemy lechenija i terminologii. Neurological Journal, 3, 33-36 (In Russian).Ruts L., Drenthen J., Jongen J. L., Hop W. C., Visser G. H., Jacobs B. C. et al. Pain in Guillain-Barre syndrome: a long-term follow-up study // Neurology. – 2010. – Vol. 75. – P. 1439-1447. DOI: 10.1212/wnl.0b013e3181f88345.Ruts, L., Drenthen, J., Jongen, J. L., Hop, W. C., Visser, G. H., Jacobs, B. C. et al. (2010). Pain in Guillain-Barre syndrome: a long-term follow-up study. Neurology, 75, 1439-1447, DOI: 10.1212/wnl.0b013e3181f88345.

The authors declare that there are no conflicts of interest present.